xylocor.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Crawl-delay: | ||
Meta Tags
| Title | XyloCor – Gene therapy for advanced coronary artery |
| Description | XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 198.46.81.218 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
xylocor.com Valuation
|
US$4,194,747
Last updated: 2023-04-30 03:42:15
xylocor.com has Semrush global rank of 2,523,228. xylocor.com has an estimated worth of US$ 4,194,747, based on its estimated Ads revenue. xylocor.com receives approximately 484,010 unique visitors each day. Its web server is located in United States, with IP address 198.46.81.218. According to SiteAdvisor, xylocor.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$4,194,747 |
| Daily Ads Revenue | US$3,873 |
| Monthly Ads Revenue | US$116,163 |
| Yearly Ads Revenue | US$1,393,947 |
| Daily Unique Visitors | 32,268 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| xylocor.com. | A | 7199 | IP: 198.46.81.218 |
| xylocor.com. | NS | 86400 | NS Record: ns.inmotionhosting.com. |
| xylocor.com. | NS | 86400 | NS Record: ns2.inmotionhosting.com. |
| xylocor.com. | MX | 14400 | MX Record: 20 d230585b.ess.barracudanetworks.com. |
| xylocor.com. | MX | 14400 | MX Record: 10 d230585a.ess.barracudanetworks.com. |
| xylocor.com. | TXT | 900 | TXT Record: v=spf1 include:spf.protection.outlook.com +a:ecbiz194.inmotionhosting.com +a:smtp.servconfig.com +a include:spf.ess.barracudanetworks.com -all |
HtmlToTextCheckTime:2023-04-30 03:42:15
| Company Approach Pipeline Angina Trial News Careers Contact XyloCor Therapeutics Gene therapy for advanced coronary artery disease XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy. Latest News Press Release: January 26, 2023 XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina More >> See Our Pipeline XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease. More >> Research & Development XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College. More >> Copyright © 2023 XyloCor Therapeutics. Website design by Foxfire Interactive |
HTTP Headers
HTTP/1.1 406 Not Acceptable Date: Fri, 22 Oct 2021 22:53:15 GMT Server: Apache Content-Type: text/html; charset=iso-8859-1 |
xylocor.com Whois Information
Domain Name: XYLOCOR.COM Registry Domain ID: 1925014974_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.tucows.com Registrar URL: http://www.tucows.com Updated Date: 2021-04-18T09:11:37Z Creation Date: 2015-05-01T18:44:19Z Registry Expiry Date: 2022-05-01T18:44:19Z Registrar: Tucows Domains Inc. Registrar IANA ID: 69 Domain Status: ok https://icann.org/epp#ok Name Server: NS.INMOTIONHOSTING.COM Name Server: NS2.INMOTIONHOSTING.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-11T12:00:59Z <<< |